Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
JD

James J. Devlin — 41 Patents

CECelera: 24 patents #1 of 75Top 2%
BLBerlex Laboratories: 9 patents #14 of 98Top 15%
PDPharmacopeia Drug Discovery: 6 patents #16 of 193Top 9%
PHPharmacopeia: 4 patents #27 of 211Top 15%
QIQuest Diagnostics Investments: 3 patents #100 of 245Top 45%
ABApplied Biosystems: 1 patents #439 of 690Top 65%
CECetus: 1 patents #118 of 213Top 60%
COCetus Oncology: 1 patents #16 of 56Top 30%
CHChiron: 1 patents #350 of 583Top 65%
Lafayette, CA: #18 of 569 inventorsTop 4%
California: #11,075 of 386,348 inventorsTop 3%
Overall (All Time): #75,001 of 4,157,543Top 2%
41 Patents All Time
James J. Devlin has been granted 41 US patents while listed as an inventor at Celera. The first was granted in 1992 and the most recent in June 2025. James J. Devlin ranks #75,001 of 4,157,543 US inventors in our database (top 1.8%). Patent records list James J. Devlin in Lafayette, CA, US.

Patents per Year

Patents granted per year, 1992 to 2025Bar chart with a peak of 7 patents in 2005.peak 71992: 1 patents19921996: 1 patents1998: 1 patents19982002: 1 patents2003: 1 patents20032004: 1 patents2005: 7 patents20052007: 1 patents2009: 2 patents20092010: 3 patents2011: 3 patents20112012: 3 patents2018: 1 patents20182019: 1 patents2020: 2 patents20202021: 5 patents2022: 2 patents20222023: 2 patents2024: 2 patents20242025: 1 patents2025

Issued Patents All Time

Showing 26–41 of 41 patents

Patent #TitleCo-InventorsDateApprox Value ⓘ
7625699 Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof May LUKE 2009-12-01 $8,114,000
7482117 Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof Michele CARGILL, Olga IAKOUBOVA 2009-01-27 $10,717,000
7306913 Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof May LUKE 2007-12-11
6887865 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2005-05-03 $357,000
6864263 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2005-03-08 $386,000
6864368 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2005-03-08 $386,000
6849739 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2005-02-01 $751,000
6846829 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2005-01-25 $396,000
6841673 N-heterocyclic derivatives as nos inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2005-01-11 $398,000
6841674 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2005-01-11 $398,000
6747031 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2004-06-08 $2,156,000
6670473 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2003-12-30
6432947 N-heterocyclic derivatives as NOS inhibitors Damian O. Arnaiz, John J. Baldwin, David D. Davey, Roland E. Dolle, Shawn David Erickson +9 more 2002-08-13
5725850 Use of CSF-1 to treat tumor burden Peter Ralph, Kong T. Chong, Robert Zimmerman, Sharon Lea Aukerman, David B. Ring +1 more 1998-03-10 $13,486,000
5556620 Use of recombinant colony stimulating factor-1 to enhance wound healing Peter Ralph, Sharon Auckerman 1996-09-17
5104650 Uses of recombinant colony stimulating factor-1 Peter Ralph, Mary Kim Warren, Kong T. Chong, Robert Zimmerman, Ada H. C. Kung 1992-04-14